Moleculin Biotech announced it has filed new patents covering the production and reconstitution of Annamycin, which is currently in two clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML).

"Annamycin already has Orphan Drug Designation for the treatment of AML," said Walter Klemp, Moleculin's Chairman and CEO, "but these new patent applications, if these patent applications are approved, would give us 20 years of protection for our drug. "Since we have recently announced promising preclinical data showing the potential for Annamycin to become an important treatment for lung metastases, having this broad coverage should add considerable value to this asset."

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com